Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun 6;12(11):e027846.
doi: 10.1161/JAHA.122.027846. Epub 2023 May 26.

Sore, Hot, and at Risk: The Emerging Specialty of Cardio-Rheumatology

Brittany Weber  1 , Michael Garshick  2   3 , Katherine P Liao  4 , Marcelo Di Carli  1
Affiliations
Editorial

Sore, Hot, and at Risk: The Emerging Specialty of Cardio-Rheumatology

Brittany Weber et al. J Am Heart Assoc. .
No abstract available

Keywords: autoimmune; cardio‐rheumatology; inflammation; prevention.

PubMed Disclaimer

Figures

Figure .
Figure .. Conceptual model of the individual components required to advance the evolving field of cardio‐rheumatology.
Shown are the key building blocks for advancing the care of patients with systemic inflammatory disorders. CV indicates cardiovascular.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res. 2015;116:307–311. doi: 10.1161/circresaha.116.301313 - DOI - PMC - PubMed
    1. Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 2014;36:482–489. doi: 10.1093/eurheartj/ehu403 - DOI - PMC - PubMed
    1. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131. doi: 10.1056/NEJMoa1707914 - DOI - PubMed
    1. Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, Insalaco A, LeWinter M, Lewis BS, Lin D, et al. Phase 3 trial of interleukin‐1 trap rilonacept in recurrent pericarditis. N Engl J Med. 2021;384:31–41. doi: 10.1056/NEJMoa2027892 - DOI - PubMed
    1. Ridker PM. From RESCUE to ZEUS: will interleukin‐6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021;117:e138–e140. doi: 10.1093/cvr/cvab231 - DOI - PMC - PubMed

Publication types